Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Long-Term Debt Repayments: 2022-2025

Historic Long-Term Debt Repayments for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to $3.

  • SAB Biotherapeutics' Long-Term Debt Repayments fell 100.00% to $3 in Q3 2025 from the same period last year, while for Sep 2025 it was $515,982, marking a year-over-year decrease of 60.52%. This contributed to the annual value of $1.3 million for FY2024, which is 25.50% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Long-Term Debt Repayments is $3, which was down 100.00% from $138,551 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Long-Term Debt Repayments registered a high of $761,050 during Q2 2022, and its lowest value of $3 during Q3 2025.
  • For the 3-year period, SAB Biotherapeutics' Long-Term Debt Repayments averaged around $235,953, with its median value being $219,649 (2024).
  • In the last 5 years, SAB Biotherapeutics' Long-Term Debt Repayments spiked by 450.36% in 2024 and then tumbled by 100.00% in 2025.
  • Over the past 4 years, SAB Biotherapeutics' Long-Term Debt Repayments (Quarterly) stood at $488,437 in 2022, then crashed by 47.59% to $255,989 in 2023, then fell by 6.19% to $240,133 in 2024, then tumbled by 100.00% to $3 in 2025.
  • Its last three reported values are $3 in Q3 2025, $138,551 for Q2 2025, and $137,295 during Q1 2025.